Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Myelofibrosis
NCT00569660Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2005
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Objective Clinical Response at 8 weeks. Started Jun 2005; status: completed.
02
Drugs
azacitidine
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00569660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00569660.